EE504 Cost-Utility Analysis Comparing Direct Oral Anticoagulant (DOAC) and Low-Molecular-Weight Heparin (LMWH) Therapies for Cancer-Associated Thrombosis (CAT) Treatment in the United States
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.750
https://www.valueinhealthjournal.com/article/S1098-3015(22)00951-2/fulltext
Title :
EE504 Cost-Utility Analysis Comparing Direct Oral Anticoagulant (DOAC) and Low-Molecular-Weight Heparin (LMWH) Therapies for Cancer-Associated Thrombosis (CAT) Treatment in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00951-2&doi=10.1016/j.jval.2022.04.750
First page :
Section Title :
Open access? :
No
Section Order :
10678